CAS 1025967-78-5: Lifitegrast
Description:Lifitegrast is a synthetic small molecule classified as a lymphocyte function-associated antigen-1 (LFA-1) antagonist. It is primarily used in the treatment of dry eye disease, a condition characterized by insufficient tear production and inflammation of the ocular surface. Lifitegrast works by inhibiting the interaction between LFA-1 on lymphocytes and intercellular adhesion molecule-1 (ICAM-1) on epithelial cells, thereby reducing inflammation and promoting ocular surface health. The substance is typically administered as an eye drop solution, allowing for localized action with minimal systemic absorption. Lifitegrast has been shown to improve symptoms of dry eye and enhance tear production in clinical studies. Its safety profile includes common side effects such as eye irritation and discomfort, but it is generally well-tolerated. As a relatively novel therapeutic agent, Lifitegrast represents a targeted approach to managing dry eye disease, addressing both symptoms and underlying inflammation.
Formula:C29H24Cl2N2O7S
InChI:InChI=1S/C29H24Cl2N2O7S/c1-41(38,39)20-4-2-3-16(11-20)12-23(29(36)37)32-27(34)25-22(30)13-19-15-33(9-7-21(19)26(25)31)28(35)18-6-5-17-8-10-40-24(17)14-18/h2-6,8,10-11,13-14,23H,7,9,12,15H2,1H3,(H,32,34)(H,36,37)/t23-/m0/s1
InChI key:InChIKey=JFOZKMSJYSPYLN-QHCPKHFHSA-N
SMILES:O=C(O)C(NC(=O)C1=C(Cl)C=C2C(=C1Cl)CCN(C(=O)C=3C=CC=4C=COC4C3)C2)CC5=CC=CC(=C5)S(=O)(=O)C